Literature DB >> 8988239

Identification of regulatory sequences in the promoter of the PDGF B-chain gene in malignant mesothelioma cell lines.

J B Prins1, A W Langerak, R P Dirks, C A Van der Linden-Van Beurden, P A De Laat, H P Bloemers, M A Versnel.   

Abstract

Platelet-derived growth factor (PDGF) B-chain mRNA is readily detectable in malignant mesothelioma (MM) cell lines, but not in normal mesothelial (NM) cell lines. The high affinity receptor for PDGF B-chain dimers, the PDGF beta-receptor, is expressed in MM cell lines. NM cell lines predominantly express the PDGF alpha-receptor. Coexpression of the PDGF beta-receptor and its ligand may lead to an autocrine growth stimulating loop in the malignant cell type. In nuclear run off experiments, PDGF B-chain mRNA was detectable in MM cells only, indicating an increased level of transcription in this cell type. The proximal promoter of the PDGF B-chain gene contains DNaseI hypersensitive (DH) sites and mediates reporter gene activation in both normal and malignant cells. Nuclear proteins, extracted from both cell types, interact with DNA sequences within the proximal promoter around bp-64 to -61 relative to the transcription start site. Electrophoretic mobility shift assays (EMSAs) indicate that these factors are more abundantly present in the malignant than in the normal cell type. A DH site around -9.9 kb was found in both cell types. When tested in CAT assays, this region exerted a stimulatory effect on transcription in malignant cells. The elevated level of transcription of the PDGF B-chain gene in malignant cells may well be the result of interaction of regulatory sites in the proximal promoter and an enhancing element located at -9.9 kb from the transcription start site.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8988239     DOI: 10.1016/s0925-4439(96)00060-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  2 in total

1.  Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.

Authors:  Anne S Tsao; Nusrat Harun; J Jack Lee; John Heymach; Katherine Pisters; Waun Ki Hong; Junya Fujimoto; Ignacio Wistuba
Journal:  Clin Lung Cancer       Date:  2013-12-27       Impact factor: 4.785

2.  Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines.

Authors:  Ombretta Melaiu; Calogerina Catalano; Chiara De Santi; Monica Cipollini; Gisella Figlioli; Lucia Pellè; Elisa Barone; Monica Evangelista; Alice Guazzelli; Laura Boldrini; Elisa Sensi; Alessandra Bonotti; Rudy Foddis; Alfonso Cristaudo; Luciano Mutti; Gabriella Fontanini; Federica Gemignani; Stefano Landi
Journal:  Genes Cancer       Date:  2017-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.